Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Alfadil Haroon: Bleeding Outcomes in Congenital Versus Acquired FXIII Deficiency
Alfadil Haroon/Photo: researchgate.net
Jun 16, 2026, 14:23

Alfadil Haroon: Bleeding Outcomes in Congenital Versus Acquired FXIII Deficiency

Alfadil Haroon, Assistant Consultant of Hematology at King Faisal Specialist Hospital and Research Centre, Assistant Professor at Alfaisal University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in HemaSphere, adding:

“Factor XIII Deficiency: Congenital versus Acquired

Study overview

  • 25 patients (52 percent congenital, 48 percent acquired)
  • Median age: 35 years

Congenital FXIII deficiency:

  • Diagnosed early (younger patients)
  • Very low FXIII levels
  • Managed with long-term prophylaxis
  • Lower bleeding risk (46 percent)

 Acquired FXIII deficiency:

  • Occurs later (median approximately 60 years)
  • Strongly linked to malignancy (92 percent)
  • Higher FXIII levels than congenital
  • Severe bleeding in 92 percent

 Bleeding Patterns:

  • Acquired FXIIID – more severe bleeding
  • GI bleeding: 41.6 percent
  • Muscle/joint: 33.3 percent

Congenital FXIIID

  • Mucosal bleeding only in this group
  • CNS bleeding similar in both groups (approximately 15–16 percent)

Key Biomarker Insight

  • FXIII level predicts bleeding only moderately
  • AUC equals 0.70
  • Best cutoff: 0.13 IU/mL

Management Highlights

Congenital: Long-term FXIII replacement (92 percent)

Acquired: Treat underlying disease (especially malignancy), FXIII plus antifibrinolytics for bleeding

Take-Home Messages

  • Congenital is not Acquired – completely different diseases
  • Acquired FXIIID equals high-risk bleeding disorder
  • FXIII level alone is not enough for risk stratification

Clinical Pearl

Patients with acquired FXIII deficiency bleed more despite higher factor levels – highlighting the importance of etiology over numbers.”

Title: Distinct Clinical Profiles and Bleeding Severity in Congenital and Acquired Factor XIII Deficiency: A Single-Center Experience

Authors: Alfadil Haroon, Tusneem Alhassan, Hazzaa Alzahrani

Alfadil Haroon: Bleeding Outcomes in Congenital Versus Acquired FXIII Deficiency

Stay updated on all scientific advances with Hemostasis Today.

Alfadil Haroon Factor XIII deficiency Hazzaa Alzahrani Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine Tusneem Alhassan
NewsFeed